<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRANDOLAPRIL</span><br/>(tran-do'la-pril)<br/><span class="topboxtradename">Mavik<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin-converting enzyme inhibitor</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Enalapril<br/><b>Pregnancy Category: </b> C first trimester (D in second and third trimester)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg, 4 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits ACE and interrupts conversion sequences initiated by renin which leads to the formation of angiotensin II from angiotensin
         I. Angiotensin II is a potent endogenous vasoconstrictor. Peripheral vascular resistance is lowered by vasodilation. Therefore
         inhibition of ACE leads to vasodilation and also to decreased circulating aldosterone. Decreased aldosterone leads to diuresis
         and a slight increase in serum potassium. All of these factors produce the antihypertensive effect of the drug.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers blood pressure by specific inhibition of ACE. Unlike other ACE inhibitors, all racial groups respond to trandolapril,
         including low-renin hypertensives.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hypertension, alone or in combination with other antihypertensive agents.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to trandolapril; history of angioedema related to previous treatment with an ACE inhibitor; pregnancy (category
         C, first trimester; category D, second and third trimesters), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, hepatic insufficiency; patients prone to hypotension (e.g., CHF, ischemic heart disease, aortic stenosis,
         CVA, dehydration); SLE, scleroderma. Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td>
<p> 				Note: Discontinue diuretics 23 d before starting trandolapril. 			</p><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg in nonblack patients, 2 mg in black patients  once daily, may increase weekly to 24 mg once daily (max: 8 mg/d)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Hepatic cirrhosis: start with 0.5 mg once daily<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li> 				Note: If concurrently ordered diuretic cannot be discontinued 23 d before beginning trandolapril therapy, reduce initial dose
            to 0.5 mg. 			
         </li>
<li>Make dosage adjustments generally at intervals of at least 1 wk.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Fatigue, <span class="speceff-life">angioedema</span>. <span class="typehead">CNS:</span> Dizziness, headache.  <span class="typehead">CV:</span> Hypotension. <span class="typehead">GI:</span> Diarrhea. <span class="typehead">Respiratory:</span> Cough. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Metabolic:</span> Hyperkalemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">diuretics</span> may enhance hypotensive effects. <span class="classification">potassium-sparing diuretics</span> (amiloride, spironolactone, triamterene), <span class="classification">potassium supplements</span>, <span class="classification">potassium-containing salt substitutes</span> may increase risk of hyperkalemia. May increase serum levels and toxicity of <b>lithium.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract and converted to active form, trandolaprilat, in liver; 70% of dose reaches systemic circulation
      as trandolaprilat. <span class="typehead">Peak:</span> 410 h. <span class="typehead">Distribution:</span> 80% protein bound; crosses placenta, secreted into breast milk of animals (human secretion unknown). <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolite, trandolaprilat. <span class="typehead">Elimination:</span> 33% excreted in urine, 66% in feces. <span class="typehead">Half-Life:</span> 6 h trandolapril, 10 h trandolaprilat. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP carefully for 13 h following initial dose, especially in patients using concurrent diuretics, on salt restriction,
            or volume depleted.
         </li>
<li>Lab tests: Monitor BP and cardiac status; serum potassium, sodium, creatinine, and ALT/SGTP; and WBC with differential periodically.</li>
<li>Monitor serum lithium levels frequently with concurrent use and assess for S&amp;S of lithium toxicity; increase caution when
            diuretic therapy is also used.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue drug and immediately report S&amp;S of angioedema of face or extremities to physician. Advise to seek emergency help
            for swelling of the tongue or any other sign of potential airway obstruction.
         </li>
<li>Be aware that light-headedness can occur, especially during early therapy. Excess fluid loss of any kind will increase risk
            of hypotension and syncope.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>